- Home
- SNDX vs MDXG Comparison
SNDX vs MDXG Comparison
Compare SNDX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- MDXG
- Stock Information
- Founded
- SNDX 2005
- MDXG 2006
- Country
- SNDX United States
- MDXG United States
- Employees
- SNDX N/A
- MDXG N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SNDX Health Care
- MDXG Health Care
- Exchange
- SNDX Nasdaq
- MDXG Nasdaq
- Market Cap
- SNDX 1.1B
- MDXG 1.1B
- IPO Year
- SNDX 2016
- MDXG N/A
- Fundamental
- Price
- SNDX $13.08
- MDXG $9.12
- Analyst Decision
- SNDX Strong Buy
- MDXG Strong Buy
- Analyst Count
- SNDX 10
- MDXG 5
- Target Price
- SNDX $36.20
- MDXG $12.00
- AVG Volume (30 Days)
- SNDX 2.6M
- MDXG 674.7K
- Earning Date
- SNDX 02-25-2025
- MDXG 02-26-2025
- Dividend Yield
- SNDX N/A
- MDXG N/A
- EPS Growth
- SNDX N/A
- MDXG N/A
- EPS
- SNDX N/A
- MDXG 0.52
- Revenue
- SNDX $16,000,000.00
- MDXG $342,804,000.00
- Revenue This Year
- SNDX N/A
- MDXG $9.56
- Revenue Next Year
- SNDX $14.15
- MDXG $9.19
- P/E Ratio
- SNDX N/A
- MDXG $18.12
- Revenue Growth
- SNDX N/A
- MDXG 10.93
- 52 Week Low
- SNDX $12.06
- MDXG $5.47
- 52 Week High
- SNDX $25.34
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SNDX 41.29
- MDXG 53.35
- Support Level
- SNDX $12.40
- MDXG $8.50
- Resistance Level
- SNDX $13.16
- MDXG $9.71
- Average True Range (ATR)
- SNDX 0.65
- MDXG 0.30
- MACD
- SNDX 0.10
- MDXG -0.04
- Stochastic Oscillator
- SNDX 39.38
- MDXG 51.24
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.